Table 2. Comparision of success rate between talc pleurodesis and control therapies at 1 month and longer than 1 month.

Assessing Time	Study/Year	Talc Pleurodesis(n/N)	Control Therapies(n/N)	RR (95% CI)	I2, P (het)	P (Z)
1 month
	Lynch/1996	8/17	18/29	0.76 (0.42–1.35)
	Diacon/2000	13/15	10/17	1.47 (0.94–2.30)
	Ong/2000	16/18	14/20	1.27 (0.91–1.77)
	Crnjac/2004	27/38	40/45	0.80 (0.64–1.00)
	Haddad/2004	33/37	30/34	1.01 (0.86–1.19)
	Paschoalini/2005	21/25	23/24	0.88 (0.72–1.06)
	Demmy/2012	15/25	23/26	0.68 (0.48–0.96)
	Overall	133/175	158/195	0.94 (0.80–1.11)	58.1%, 0.026	0.455
Longer than 1 month
	Fentiman/1983	18/20	9/17	1.70 (1.06–2.72)
	Sorensen/1984	9/9	7/12	1.65 (1.01–2.68)
	Fentiman/1986	11/12	10/21	1.92 (1.19–3.11)
	Hamed/1989	10/10	10/15	1.45 (1.00–2.12)
	Diacon/2000	13/15	6/17	2.46 (1.25–4.82)
	Kuzdzal/2003	17/18	1/13	12.28 (1.86–80.98)
	Haddad/2004	30/37	23/34	1.20 (0.91–1.59)
	Crnjac/2004	23/34	33/39	0.80 (0.61–1.05)
	Das/2008	19/24	24/28	0.92 (0.72–1.19)
	Mohsen/2011	19/22	17/20	1.02(0.79–1.30)
	Davis/2012	36/48	26/51	1.47 (1.07–2.02)
	Overall	205/249	166/267	1.35 (1.07 − 1.69)	74.9%, <0.001	0.010

n = the number of patients with successful pleurodesis; N = the number of evaluable patients for outcome; RR = relative risk;

CI = confidence interval.